Skip header and navigation

Refine By

11 records – page 1 of 2.

Accuracy of Canadian health administrative databases in identifying patients with rheumatoid arthritis: a validation study using the medical records of rheumatologists.

https://arctichealth.org/en/permalink/ahliterature114676
Source
Arthritis Care Res (Hoboken). 2013 Oct;65(10):1582-91
Publication Type
Article
Date
Oct-2013
Author
Jessica Widdifield
Sasha Bernatsky
J Michael Paterson
Karen Tu
Ryan Ng
J Carter Thorne
Janet E Pope
Claire Bombardier
Author Affiliation
University of Toronto, Toronto, Ontario, Canada.
Source
Arthritis Care Res (Hoboken). 2013 Oct;65(10):1582-91
Date
Oct-2013
Language
English
Publication Type
Article
Keywords
Adult
Aged
Algorithms
Arthritis, Rheumatoid - diagnosis - epidemiology
Data Mining - statistics & numerical data
Databases, Factual - statistics & numerical data
Drug Prescriptions - statistics & numerical data
Fees and Charges - statistics & numerical data
Female
Hospitalization - statistics & numerical data
Humans
Male
Medical Records Systems, Computerized - statistics & numerical data
Middle Aged
Ontario - epidemiology
Reproducibility of Results
Retrospective Studies
Rheumatology - statistics & numerical data
Single-Payer System - statistics & numerical data
Abstract
Health administrative data can be a valuable tool for disease surveillance and research. Few studies have rigorously evaluated the accuracy of administrative databases for identifying rheumatoid arthritis (RA) patients. Our aim was to validate administrative data algorithms to identify RA patients in Ontario, Canada.
We performed a retrospective review of a random sample of 450 patients from 18 rheumatology clinics. Using rheumatologist-reported diagnosis as the reference standard, we tested and validated different combinations of physician billing, hospitalization, and pharmacy data.
One hundred forty-nine rheumatology patients were classified as having RA and 301 were classified as not having RA based on our reference standard definition (study RA prevalence 33%). Overall, algorithms that included physician billings had excellent sensitivity (range 94-100%). Specificity and positive predictive value (PPV) were modest to excellent and increased when algorithms included multiple physician claims or specialist claims. The addition of RA medications did not significantly improve algorithm performance. The algorithm of "(1 hospitalization RA code ever) OR (3 physician RA diagnosis codes [claims] with =1 by a specialist in a 2-year period)" had a sensitivity of 97%, specificity of 85%, PPV of 76%, and negative predictive value of 98%. Most RA patients (84%) had an RA diagnosis code present in the administrative data within ±1 year of a rheumatologist's documented diagnosis date.
We demonstrated that administrative data can be used to identify RA patients with a high degree of accuracy. RA diagnosis date and disease duration are fairly well estimated from administrative data in jurisdictions of universal health care insurance.
PubMed ID
23592598 View in PubMed
Less detail

Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes.

https://arctichealth.org/en/permalink/ahliterature116618
Source
J Rheumatol. 2013 Aug;40(8):1259-67
Publication Type
Article
Date
Aug-2013
Author
Lillian Barra
Vivian Bykerk
Janet E Pope
Boulos P Haraoui
Carol A Hitchon
J Carter Thorne
Edward C Keystone
Gilles Boire
Author Affiliation
Department of Medicine, Division of Rheumatology, St. Joseph's Health Care London, University of Western Ontario, London, Ontario, Canada. lbarra2@uwo.ca
Source
J Rheumatol. 2013 Aug;40(8):1259-67
Date
Aug-2013
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antibodies, Anti-Idiotypic - blood
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - blood - drug therapy
Biological Markers - blood
Canada
Cohort Studies
Disability Evaluation
Female
Follow-Up Studies
Humans
Male
Middle Aged
Peptides, Cyclic - immunology
Predictive value of tests
Questionnaires
Regression Analysis
Rheumatoid Factor - blood
Sensitivity and specificity
Severity of Illness Index
Treatment Outcome
Abstract
In inflammatory arthritis, rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPA) are believed to be associated with more severe clinical outcomes. Our objective was to determine whether ACPA and RF remain stable in early inflammatory arthritis and whether their trajectories over time or baseline levels predicted clinical outcomes.
The study population consisted of patients enrolled in the Canadian Early Arthritis Cohort Study with baseline and at least 12-month followup values of RF and ACPA. Primary outcomes were Disease Activity Score (DAS) remission and the presence of erosions at 12 and 24 months. Other objectives included swollen joint count, Health Assessment Questionnaire score, and DAS.
At baseline, 225/342 (66%) patients were ACPA-positive and 334/520 (64%) were RF-positive. At 24 months, 15/181 (8%) ACPA-positive patients became negative. A larger number of patients changed from ACPA-negative to positive: 13/123 (11%). For RF, fluctuations were more common: 67/240 (28%) reverted from positive to negative and 21/136 (18%) converted from negative to positive. RF and ACPA fluctuations did not predict disease outcomes. Patients who remained ACPA-positive throughout followup were more likely to have erosive disease (OR 3.86, 95% CI 1.68, 8.92).
RF and ACPA have the potential to revert and convert during the early course of disease. Fluctuations in RF and ACPA were not associated with clinical outcomes.
PubMed ID
23378461 View in PubMed
Less detail

The Canadian Early Arthritis Cohort (CATCH): patients with new-onset synovitis meeting the 2010 ACR/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activity.

https://arctichealth.org/en/permalink/ahliterature121576
Source
J Rheumatol. 2012 Nov;39(11):2071-80
Publication Type
Article
Date
Nov-2012
Author
Vivian P Bykerk
Shahin Jamal
Gilles Boire
Carol A Hitchon
Boulos Haraoui
Janet E Pope
J Carter Thorne
Ye Sun
Edward C Keystone
Author Affiliation
Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. vbykerk@gmail.com
Source
J Rheumatol. 2012 Nov;39(11):2071-80
Date
Nov-2012
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antirheumatic Agents - therapeutic use
Canada
Cohort Studies
Europe
Female
Finger Joint - radiography
Humans
Male
Methotrexate - therapeutic use
Middle Aged
Patient Selection
Prospective Studies
Rheumatoid Factor - blood
Severity of Illness Index
Societies, Medical
Synovitis - classification - diagnosis - drug therapy
United States
Abstract
Our objective was to describe characteristics of Canadian patients with early arthritis and examine differences between those fulfilling 1987 and 2010 rheumatoid arthritis (RA) classification criteria.
The Canadian Early Arthritis Cohort (CATCH) is a national, multicenter, observational, prospective cohort of patients with early inflammatory arthritis, receiving usual care, recruited since 2007. Inclusion criteria include age > 16 years; symptom duration 6-52 weeks; swelling of = 2 joints or = 1 metacarpophalangeal/proximal interphalangeal joint; and 1 of rheumatoid factor = 20 IU, positive anticitrullinated protein antibodies (ACPA), morning stiffness = 45 min, response to nonsteroidal antiinflammatory drug, or positive metatarsophalangeal joint squeeze test. Data from patients enrolled to March 15, 2011, were analyzed.
In total, 1450 patients met the eligibility criteria (1187 were followed). At baseline, mean age was 53 ± 15 years, symptom duration was 6.1 ± 3.2 months, Disease Activity Score (DAS28) was 4.9 ± 1.6, Health Assessment Questionnaire-Disability Index was 1.0 ± 0.7. Forty-one percent (n = 450) of patients had moderate (3.2 5.1) disease activity; 28% of those with baseline radiographs (n = 250/908) had radiographic evidence of erosions. ACPA status was available for 70% (n = 831) of patients; 55% (n = 453) tested positive. Sixty percent (n = 718) of patients were treated with methotrexate (MTX) initially. Of 612 patients without erosions, 63% and 83% fulfilled 1987 and 2010 RA classification criteria, respectively. Seventy-three percent (n = 166) of those who did not fulfill 1987 criteria were newly identified by the 2010 criteria. These patients had less severe disease and more were MTX-naive compared to those satisfying the 1987 criteria. Forty-seven percent of all patients achieved remission at 1 year.
Patients with early RA present with moderate high disease activity;
Notes
Comment In: J Rheumatol. 2012 Nov;39(11):2062-323118277
PubMed ID
22896026 View in PubMed
Less detail

Canadian recommendations for clinical trials of pharmacologic interventions in rheumatoid arthritis: inclusion criteria and study design.

https://arctichealth.org/en/permalink/ahliterature132908
Source
J Rheumatol. 2011 Oct;38(10):2095-104
Publication Type
Article
Date
Oct-2011
Author
Jacob Karsh
Edward C Keystone
Boulos Haraoui
J Carter Thorne
Janet E Pope
Vivian P Bykerk
Walter P Maksymowych
Michel Zummer
William G Bensen
Majed M Kraishi
Author Affiliation
The Ottawa Hospital, Riverside Campus, 1967 Riverside Drive, Ottawa, ON K1H 7W9, Canada. jkarsh@ottawahospital.on.ca
Source
J Rheumatol. 2011 Oct;38(10):2095-104
Date
Oct-2011
Language
English
Publication Type
Article
Keywords
Arthritis, Rheumatoid - drug therapy
Canada
Clinical Trials as Topic
Humans
Patient Selection
Research Design
Abstract
Current clinical trial designs for pharmacologic interventions in rheumatoid arthritis (RA) do not reflect the innovations in RA diagnosis, treatment, and care in countries where new drugs are most often used. The objective of this project was to recommend revised entry criteria and other study design features for RA clinical trials.
Recommendations were developed using a modified nominal group consensus method. Canadian Rheumatology Research Consortium (CRRC) members were polled to rank the greatest challenges to clinical trial recruitment in their practices. Initial recommendations were developed by an expert panel of rheumatology trialists and other experts. A scoping study methodology was then used to examine the evidence available to support or refute each initial recommendation. The potential influence of CRRC recommendations on primary outcomes in future trials was examined. Recommendations were finalized using a consensus process.
Recommendations for clinical trial inclusion criteria addressed measures of disease activity [Disease Activity Score 28 using erythrocyte sedimentation rate (DAS28-ESR) > 3.2 PLUS = 3 tender joints using 28-joint count (TJC28) PLUS = 3 swollen joint (SJC28) OR C-reactive protein (CRP) or ESR > upper limit of normal PLUS = 3 TJC28 PLUS = 3 SJC28], functional classification, disease classification and duration, and concomitant RA treatments. Additional recommendations regarding study design addressed rescue strategies and longterm extension.
There is an urgent need to modify clinical trial inclusion criteria and other study design features to better reflect the current characteristics of people living with RA in the countries where the new drugs will be used.
Notes
Comment In: J Rheumatol. 2011 Oct;38(10):2087-821965690
PubMed ID
21765109 View in PubMed
Less detail

Determining best practices in early rheumatoid arthritis by comparing differences in treatment at sites in the Canadian Early Arthritis Cohort.

https://arctichealth.org/en/permalink/ahliterature107248
Source
J Rheumatol. 2013 Nov;40(11):1823-30
Publication Type
Article
Date
Nov-2013
Author
Jamie A Harris
Vivian P Bykerk
Carol A Hitchon
E C Keystone
J Carter Thorne
Gilles Boire
Boulos Haraoui
Glen Hazlewood
Ashley J Bonner
Janet E Pope
Author Affiliation
From the Rheumatology Centre, St. Joseph's Health Care, London, Ontario, Canada; the Hospital for Special Surgery, New York, New York, USA; the Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; the University of Toronto, Toronto; Southlake Regional Health Centre, Newmarket, Ontario; the Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke, Sherbrooke, Quebec; the Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; McMaster University, Hamilton, Ontario; and Western University, London, Ontario, Canada.
Source
J Rheumatol. 2013 Nov;40(11):1823-30
Date
Nov-2013
Language
English
Publication Type
Article
Keywords
Adult
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Canada
Disease Progression
Drug Therapy, Combination
Female
Humans
Male
Methotrexate - therapeutic use
Middle Aged
Practice Guidelines as Topic
Remission Induction - methods
Severity of Illness Index
Standard of Care
Treatment Outcome
Abstract
To determine site variation by comparing outcomes across sites in an early rheumatoid arthritis cohort.
Sites from the Canadian Early Arthritis Cohort database with at least 40 patients were studied. Comparisons were made among sites in change in 28-joint Disease Activity Score (DAS28), proportion of patients in DAS28 remission, and treatment strategies.
The study included 1138 baseline patients at 8 sites, with baseline (SD) age 52 years (16.9); 72% women; 23% erosions; 54% ever smokers; 51% rheumatoid factor-positive; 37% anticitrullinated protein antibody-positive; disease duration 187 (203) days; DAS28 4.5 (1.4). Site had an effect on outcomes when adjusting for confounders. At 6 and 12 months, sites B and H, the 2 largest sites, had the best changes in DAS28 (-1.82 and -2.09, respectively, at 6 mos, and -2.27 for both at 12 mos; p
PubMed ID
24037554 View in PubMed
Less detail

The epidemiology of rheumatoid arthritis in Ontario, Canada.

https://arctichealth.org/en/permalink/ahliterature104423
Source
Arthritis Rheumatol. 2014 Apr;66(4):786-93
Publication Type
Article
Date
Apr-2014
Author
Jessica Widdifield
J Michael Paterson
Sasha Bernatsky
Karen Tu
George Tomlinson
Bindee Kuriya
J Carter Thorne
Claire Bombardier
Author Affiliation
University of Toronto and Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
Source
Arthritis Rheumatol. 2014 Apr;66(4):786-93
Date
Apr-2014
Language
English
Publication Type
Article
Keywords
Adult
Aged
Arthritis, Rheumatoid - epidemiology
Databases, Factual
Female
Humans
Incidence
Male
Middle Aged
Ontario - epidemiology
Prevalence
Abstract
Epidemiologic assessments of sufficiently large populations are required in order to obtain robust estimates of disease prevalence and incidence, particularly when exploring the influence of various factors (age, sex, calendar time). We undertook this study to describe the epidemiology of rheumatoid arthritis (RA) over the past 15 years.
We used the Ontario Rheumatoid Arthritis administrative Database (ORAD), a validated population-based research database of all Ontarians with RA. The ORAD records were linked with census data to calculate crude and age and sex-standardized prevalence and incidence rates from 1996 to 2010. Vital statistics were used to estimate annual all-cause mortality during the study period.
As of 2010, there were 97,499 Ontarians with RA, corresponding to a cumulative prevalence of 0.9%. Age and sex-standardized RA prevalence increased steadily over time from 473 (95% confidence interval [95% CI] 469-478) per 100,000 population (0.49%) in 1996 to 784 (95% CI 779-789) per 100,000 population (0.9%) in 2010. Age and sex-standardized incidence per 100,000 population ranged from 62 (95% CI 60-63) in 1996 to 54 (95% CI 52-55) in 2010. All-cause mortality decreased by a relative 21.4% since 1996.
Over a 15-year period, we observed an increase in RA prevalence over time. This rise may be attributed to the increasing time to ascertain cases (which may have been latent in the population during earlier years of the study), increasing survival, and/or an increase in the aging background population. Incidence appears to be stable.
PubMed ID
24757131 View in PubMed
Less detail

Incidence and predictors of secondary fibromyalgia in an early arthritis cohort.

https://arctichealth.org/en/permalink/ahliterature122649
Source
Ann Rheum Dis. 2013 Jun;72(6):949-54
Publication Type
Article
Date
Jun-2013
Author
Yvonne C Lee
Bing Lu
Gilles Boire
Boulos Paul Haraoui
Carol A Hitchon
Janet E Pope
J Carter Thorne
Edward Clark Keystone
Daniel H Solomon
Vivian P Bykerk
Author Affiliation
Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. ylee9@partners.org
Source
Ann Rheum Dis. 2013 Jun;72(6):949-54
Date
Jun-2013
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antibodies - immunology
Arthritis - epidemiology
Arthritis, Rheumatoid - epidemiology
Canada - epidemiology
Cohort Studies
Female
Fibromyalgia - epidemiology
Humans
Incidence
Male
Mental Disorders - epidemiology
Middle Aged
Pain Measurement
Peptides, Cyclic - immunology
Proportional Hazards Models
Prospective Studies
Risk factors
Severity of Illness Index
Abstract
Secondary fibromyalgia (FM) is common among patients with inflammatory arthritis, but little is known about its incidence and the factors leading to its development. The authors examined the incidence of secondary FM in an early inflammatory arthritis cohort, and assessed the association between pain, inflammation, psychosocial variables and the clinical diagnosis of FM.
Data from 1487 patients in the Canadian Early Arthritis Cohort, a prospective, observational Canadian cohort of early inflammatory arthritis patients were analysed. Diagnoses of FM were determined by rheumatologists. Incidence rates were calculated, and Cox regression models were used to determine HRs for FM risk.
The cumulative incidence rate was 6.77 (95% CI 5.19 to 8.64) per 100 person-years during the first 12 months after inflammatory arthritis diagnosis, and decreased to 3.58 (95% CI 1.86 to 6.17) per 100 person-years 12-24 months after arthritis diagnosis. Pain severity (HR 2.01, 95% CI 1.17 to 3.46) and poor mental health (HR 1.99, 95% CI 1.09 to 3.62) predicted FM risk. Citrullinated peptide positivity (HR 0.48, 95% CI 0.26 to 0.88) was associated with decreased FM risk. Serum inflammatory markers and swollen joint count were not significantly associated with FM risk.
The incidence of FM was from 3.58 to 6.77 cases per 100 person-years, and was highest during the first 12 months after diagnosis of inflammatory arthritis. Although inflammation was not associated with the clinical diagnosis of FM, pain severity and poor mental health were associated with the clinical diagnosis of FM. Seropositivity was inversely associated with the clinical diagnosis of FM.
Notes
Cites: Arthritis Rheum. 2005 Dec;52(12):3685-9216329076
Cites: Semin Arthritis Rheum. 2008 Oct;38(2):101-918221987
Cites: J Rheumatol. 2007 Apr;34(4):810-717299839
Cites: Rheumatology (Oxford). 2007 Jun;46(6):1009-1417401133
Cites: Clin Exp Rheumatol. 2007 Mar-Apr;25(2):225-3017543146
Cites: J Rheumatol. 2007 Jun;34(6):1415-2517552068
Cites: J Rheumatol. 2007 Dec;34(12):2382-717985407
Cites: Arthritis Rheum. 2009 Jun 15;61(6):794-80019479706
Cites: Arthritis Res Ther. 2009;11(3):R6119413909
Cites: Glia. 2009 Nov 1;57(14):1469-7919306358
Cites: Arthritis Res Ther. 2009;11(5):R16019874580
Cites: Rheumatology (Oxford). 2010 May;49(5):924-820100795
Cites: Semin Arthritis Rheum. 2010 Jun;39(6):448-5319250656
Cites: Semin Arthritis Rheum. 2010 Aug;40(1):15-3119217649
Cites: Ann Rheum Dis. 2010 Sep;69(9):1580-820699241
Cites: J Vasc Interv Radiol. 2010 Sep;21(9):1405-920800779
Cites: Arthritis Care Res (Hoboken). 2010 Oct;62(10):1370-620506177
Cites: J Rheumatol. 2010 Nov;37(11):2221-520716658
Cites: Pain Med. 2010 Sep;11(9):1391-40020735749
Cites: J Pain. 2010 Dec;11(12):1320-820488762
Cites: Pain. 2011 Feb;152(2):291-920961687
Cites: Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3731-621245297
Cites: Ann Rheum Dis. 2011 Jun;70(6):935-4221540201
Cites: J Rheumatol. 2011 Jun;38(6):1113-2221285161
Cites: Am J Epidemiol. 2011 Aug 1;174(3):267-7321633119
Cites: J Rheumatol. 2011 Aug;38(8):1546-5121632678
Cites: J Rheumatol. 2011 Oct;38(10):2238-4621765102
Cites: Arthritis Res Ther. 2011;13(2):21121542893
Cites: Best Pract Res Clin Rheumatol. 2011 Apr;25(2):165-7122094193
Cites: Semin Arthritis Rheum. 2011 Dec;41(3):319-3421665248
Cites: J Rheumatol. 2012 Jan;39(1):22-722002014
Cites: Arthritis Rheum. 2012 Jan;64(1):281-422081440
Cites: J Rheumatol. 1999 Nov;26(11):2458-6710555910
Cites: Pain. 2000 Apr;85(3):483-9110781923
Cites: Eur J Pain. 2002;6(2):161-7611900476
Cites: Pain. 2002 Sep;99(1-2):49-5912237183
Cites: Pain. 2003 Mar;102(1-2):87-9512620600
Cites: Lupus. 2003;12(4):274-912729050
Cites: Best Pract Res Clin Rheumatol. 2003 Aug;17(4):685-70112849719
Cites: J Rheumatol. 2004 Apr;31(4):695-70015088293
Cites: Clin Rheumatol. 1989 Dec;8(4):467-742612115
Cites: J Rheumatol. 1992 Jun;19(6):851-51404120
Cites: Med Care. 1996 Mar;34(3):220-338628042
Cites: J Rheumatol. 1999 Jul;26(7):1570-610405947
Cites: Arthritis Rheum. 2007 Dec;56(12):4015-2318050216
Cites: J Neurosci. 2008 May 14;28(20):5189-9418480275
Cites: J Pain. 2006 Sep;7(9):626-3416942948
PubMed ID
22791744 View in PubMed
Less detail

Increasing treatment in early rheumatoid arthritis is not determined by the disease activity score but by physician global assessment: results from the CATCH study.

https://arctichealth.org/en/permalink/ahliterature121074
Source
J Rheumatol. 2012 Nov;39(11):2081-7
Publication Type
Article
Date
Nov-2012
Author
Lonnie Pyne
Vivian P Bykerk
Gilles Boire
Boulos Haraoui
Carol Hitchon
J Carter Thorne
Edward C Keystone
Janet E Pope
Author Affiliation
Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
Source
J Rheumatol. 2012 Nov;39(11):2081-7
Date
Nov-2012
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Canada
Cohort Studies
Decision Making
Disability Evaluation
Dose-Response Relationship, Drug
Female
Humans
Male
Middle Aged
Physicians
Prospective Studies
Regression Analysis
Severity of Illness Index
Abstract
To determine the factors most strongly associated with an increase in therapy of early rheumatoid arthritis (ERA).
Data from the Canadian Early Arthritis Cohort (CATCH) were included if the patient had = 2 visits and baseline and 6 months data. A regression analysis was done to determine factors associated with treatment intensification.
Of 1145 patients with ERA, 790 met inclusion criteria; mean age was 53.4 years (SD 14.7), mean disease duration 6.1 months (SD 2.8), 75% were female, baseline Disease Activity Score-28 (DAS28) was 4.7 (SD 1.8) and 2.9 (SD 1.8) at 6 months for included patients. Univariate factors for intensifying treatment were physician global assessment (MDGA; OR 7.8 and OR 7.4 at 3 and 6 months, respectively, p
Notes
Comment In: J Rheumatol. 2012 Nov;39(11):2064-523118278
PubMed ID
22942265 View in PubMed
Less detail

Low prevalence of work disability in early inflammatory arthritis (EIA) and early rheumatoid arthritis at enrollment into a multi-site registry: results from the catch cohort.

https://arctichealth.org/en/permalink/ahliterature125685
Source
Rheumatol Int. 2013 Feb;33(2):457-65
Publication Type
Article
Date
Feb-2013
Author
Lauren Mussen
Tristan Boyd
Vivian Bykerk
Faye de Leon
Lihua Li
Gilles Boire
Carol Hitchon
Boulos Haraoui
J Carter Thorne
Janet Pope
Author Affiliation
Division of Rheumatology, Department of Medicine, St Joseph's Health Care, Western University, 268 Grosvenor St., London, ON N6A 4V2, Canada.
Source
Rheumatol Int. 2013 Feb;33(2):457-65
Date
Feb-2013
Language
English
Publication Type
Article
Keywords
Adult
Aged
Arthritis - complications
Arthritis, Rheumatoid - complications
Autoantibodies - blood
Canada
Cohort Studies
Employment
Female
Humans
Male
Middle Aged
Peptides, Cyclic - immunology
Registries
Sick Leave - statistics & numerical data
Abstract
We determined the prevalence of work disability in early rheumatoid arthritis (ERA) and undifferentiated early inflammatory arthritis (EIA) patients at first enrollment into the Canadian Early Arthritis Cohort (CATCH) who met the 2010 ACR criteria versus those not meeting criteria, to determine the impact of meeting new criteria on work disability status. Data at first visit into the cohort were analyzed. Descriptive statistics and logistic regression analyses were performed to investigate the association of other variables in our database with work disability. 1,487 patients were enrolled in the CATCH study, a multi-site observational, prospective cohort of patients with EIA. 934 patients were excluded (505 based on missing criteria for ACR 2010 classification, as anti-CCP was absent, and 429 were not working for other reasons). Of the 553 patients included, 71 % were female with mean disease duration of 6.4 months. 524 (94.8 %) were employed while 29 (5.2 %) reported work disability at first visit. There were no differences between those meeting 2010 ACR criteria versus those who did not. Baseline characteristics associated with work disability were male gender, age, education, income, HAQ, and positive RF status. The mean HAQ score in work disabled patients was 1.4 versus 0.9 in those who were working (p 50 years; p = 0.3), lower education (p = 0.3) or RF positivity (p = 0.6). We found rates of work disability to be low at entry into this EIA cohort compared to previous studies. There may be potential for intervention in ERA to prevent the development of work disability.
PubMed ID
22461187 View in PubMed
Less detail

Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective.

https://arctichealth.org/en/permalink/ahliterature141136
Source
Arthritis Care Res (Hoboken). 2011 Jan;63(1):53-7
Publication Type
Article
Date
Jan-2011
Author
Jessica Widdifield
Sasha Bernatsky
J Michael Paterson
J Carter Thorne
Alfred Cividino
Janet Pope
Nadia Gunraj
Claire Bombardier
Author Affiliation
University of Toronto, Toronto, Ontario, Canada.
Source
Arthritis Care Res (Hoboken). 2011 Jan;63(1):53-7
Date
Jan-2011
Language
English
Publication Type
Article
Keywords
Age of Onset
Aged
Aged, 80 and over
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - epidemiology - therapy
Cohort Studies
Female
Humans
Male
Ontario - epidemiology
Quality of Health Care - standards - trends
Abstract
To estimate the percentage of seniors with rheumatoid arthritis (RA) receiving disease-modifying antirheumatic drugs (DMARDs) within the first year of diagnosis.
We assembled an incident RA cohort from Ontario physician billing data for 1997-2006. We used a standard algorithm to identify 24,942 seniors with RA based on = 2 billing codes = 60 days apart but within 5 years. Drug exposures were obtained from pharmacy claims data. We followed subjects for 1 year, assessing if they had been exposed (defined as = 1 prescription) to 1 or more DMARDs within the first year of RA diagnosis. We assessed secular trends and differences for subjects who had received rheumatology care (defined as = 1 rheumatology encounter) versus those who had not.
In total, only 39% of the 24,942 seniors with new-onset RA identified over 1997-2006 were exposed to DMARD therapy within 1 year of diagnosis. This increased from 30% in 1997 to 53% in 2006. Patients whose care involved a rheumatologist were more likely to be exposed to DMARDs than those who had no rheumatology care. In 2006, 67% of subjects receiving rheumatology care were exposed to DMARDs versus 21% of those with no rheumatology care.
Improvements in RA care have occurred, but more efforts are needed. Subjects receiving rheumatology care are much more likely to receive DMARDs as compared to those with no rheumatology care. This emphasizes the key role of rheumatologists.
PubMed ID
20806274 View in PubMed
Less detail

11 records – page 1 of 2.